OSOVSKA, Marcela, Andrea JANÍKOVÁ, Leoš KŘEN and Andrea MAREČKOVÁ. Chronic Benign CD8+Proliferation: A Rare Affection that Can Mimic a Lymphoma Relapse. CASE REPORTS IN HEMATOLOGY. LONDON: HINDAWI LTD, 2019, vol. 2019, No 4932616, p. 1-4. ISSN 2090-6560. Available from: https://dx.doi.org/10.1155/2019/4932616.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Chronic Benign CD8+Proliferation: A Rare Affection that Can Mimic a Lymphoma Relapse
Authors OSOVSKA, Marcela (203 Czech Republic), Andrea JANÍKOVÁ (203 Czech Republic, belonging to the institution), Leoš KŘEN (203 Czech Republic, belonging to the institution) and Andrea MAREČKOVÁ (203 Czech Republic, belonging to the institution).
Edition CASE REPORTS IN HEMATOLOGY, LONDON, HINDAWI LTD, 2019, 2090-6560.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/19:00109676
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1155/2019/4932616
UT WoS 000461613800001
Keywords in English Chronic benign CD8+ proliferation
Tags 14110212, 14110230, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 8/6/2020 08:59.
Abstract
Chronic benign CD8+ proliferation is a rare syndrome that can take the form of a variety of other diseases. Peripheral adenopathy, cytopenia, and infiltration of the liver, kidneys, bowels, or other organs are the most common clinical presentations of the syndrome. CD8+ expansion can be clonal and nonclonal. It generally occurs in patients with innate or acquired immunodeficiency (HIV+) or in patients receiving immunosuppressive therapy. It has been found repeatedly in patients who developed severe hypogammaglobulinemia after treatment with rituximab. Diagnosis of the disease can be difficult because it can mimic relapse of a lymphoma, and a common biopsy examination cannot identify the problem at first. The authors describe a case of a patient pretreated with rituximab who developed agammaglobulinemia and peripheral adenopathy. Biopsy of an enlarged lymph node showed reactive lymphadenitis. Additionally, a flow-cytometric examination revealed a pathological population of CD8+ lymphocytes. The treatment, which differed from treatments of lymphoma relapse, consisted of corticosteroids and IVIG substitutions and has led to a regression of clinical symptoms. With more frequent usage of rituximab, one can expect increased occurrence of a very rare CD8+ expansion that can reliably emulate the relapse of a lymphoma.
PrintDisplayed: 16/6/2024 11:36